Key result
Tenecteplase matches alteplase in functional outcomes and safety for acute ischemic stroke.
Why the study?
Recent advances in thrombolytic agents, imaging-based patient selection, and evolving clinical guidelines have transformed IVT for AIS from a strictly time-restricted therapy into a precision-guided reperfusion strategy, motivating a synthesis of current evidence on pivotal agents, therapeutic time windows, and contemporary stroke management.
Does imaging-guided intravenous thrombolysis with tenecteplase or alteplase improve functional outcomes and maintain safety in patients with acute ischemic stroke?
Does imaging-guided intravenous thrombolysis with tenecteplase or alteplase improve functional outcomes and maintain safety in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
Intravenous thrombolysis for acute ischemic stroke has evolved from a rigid time-based therapy into an imaging-guided precision intervention, highlighted by the transition toward single-bolus tenecteplase 0.25 mg/kg and tissue-based selection in extended time windows.
Introduction: Intravenous thrombolysis (IVT) remains the foundational pharmacologic therapy for acute ischemic stroke (AIS), targeting restoration of cerebral perfusion and preservation of the ischemic penumbra. Recent advances in thrombolytic agents, imaging-based patient selection, and evolving clinical guidelines have transformed IVT from a strictly time-restricted therapy into a precision-guided reperfusion strategy. This review aims to synthesize current evidence on pivotal thrombolytic agents, the evolution of therapeutic time windows, and contemporary shifts in guideline-directed stroke management. Methods: A narrative review was conducted using PubMed/MEDLINE, Scopus, and Science Direct. Evidence from randomized controlled trials, meta-analyses, cohorts, and guidelines was synthesized. Focus areas included thrombolytic agents, therapeutic window evolution, imaging-guided selection, integration with mechanical thrombectomy, and safety considerations. Results: While alteplase remains an established agent, tenecteplase at 0.25 mg/kg demonstrates non-inferior functional outcomes with comparable safety and operational advantages, particularly single-bolus administration. Advanced imaging using CT perfusion and diffusion-weighted MRI enables tissue-based selection, supporting IVT in extended windows and in wake-up strokes when viable penumbra is present. IVT continues to complement mechanical thrombectomy in selected patients, although direct-to-thrombectomy strategies are under evaluation. Symptomatic intracranial hemorrhage remains the principal complication, with current data indicating similar safety profiles for tenecteplase and alteplase. Conclusion: IVT has evolved from a rigid time-restricted therapy to an imaging-guided precision intervention. The transition toward tenecteplase and tissue-based eligibility represents a major paradigm shift, ensuring IVT remains a central, accessible component of modern, physiology-driven stroke reperfusion care.
No takes yet. Share an insight, caveat, or question.
CHANGAY et al. (2026) conducted a review in Acute ischemic stroke (AIS). Intravenous thrombolysis (tenecteplase or alteplase) vs. Alteplase was evaluated on Functional outcomes and symptomatic intracranial hemorrhage. Tenecteplase at /kg demonstrates non-inferior functional outcomes and comparable safety to alteplase in acute ischemic stroke, alongside imaging-guided selection in extended windows.
Synapse has enriched 10 related papers. Consider them for comparative context: